ANXA5

(redirected from Annexin A5)
Also found in: Wikipedia.

ANXA5

A gene on chromosome 4q27 that encodes annexin 5, a calcium-dependent phospholipid-binding protein that inhibits phospholipase A2 and protein kinase C kinase, has anticoagulant activity, and may have a role in cell signal transduction, inflammation, growth and differentiation.
References in periodicals archive ?
Athera Biotechnologies AB, has transferred the rights to the recombinant Annexin A5 to Medirista AB.
Recombinant Annexin A5 has been developed to preclinical stage by Athera as an anti-inflammatory therapy, primarily targeting prevention of complications following vascular surgery.
4) These include APA interference with endogenous anticoagulant mechanisms (disruption of the annexin A5 anticoagulant shield, (5) inhibition of the protein C pathway, inhibition of antithrombin), binding and activation of platelets, interactions with endothelial cells inducing expression of adhesion molecules and tissue factor, and activation of the complement cascade.
Resistance to annexin A5 anticoagulant activity: a thrombogenic mechanism for the antiphospholipid syndrome.
3 provirus ancestral Env polyprotein 32 Hippocalcin-like protein 1 (Visinin-like protein 3) (VILIP-3) 33 Non-muscle caldesmon 43 Annexin A5 (Annexin V) (Lipocortin V) (Endonexin II) 44 Calpain small subunit 1 (CSS1) 48 Heat shock cognate 71 kDa protein (Heat shock 70 kDa protein 8) 49 60 kDa heat shock protein, mitochondrial precursor (Hsp60) 57 Prolyl 4-hydroxylase alpha-2 subunit precursor (EC 1.
The recombinant protein Annexin A5 is intended for the treatment of patients with Acute Coronary Syndrome and who are at imminent risk for Myocardial Infarction.
Annexin A5 is a biotechnology product produced using Richter-Helm's proprietary E.